Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM renal transplant study of everolimus with reduced calcineurin inhibitor versus mycophenolic acid with standard calcineurin inhibitor
NL-OMON44739Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus, mycophenolic acid, tacrolimus and cyclosporine in kidney transplant (2 arms), sponsored by Novartis. Started Mar 2014; status: active, not recruiting.
02
Drugs
everolimusmycophenolic acidtacrolimuscyclosporine
03
Conditions
kidney transplant
Beyond the preview
Go deeper on NL-OMON44739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44739.